Skip to main content
ESMO Early Breast Cancer
Interview with the Innovators
Recent Clinical Trials of Neoadjuvant Immunotherapy in Breast Cancer
Nadia Harbeck, MD, PhD
Read More
FDA Updates
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Read More
ESMO Early Breast Cancer
Interview with the Innovators
New Developments on Prognostic Markers for Patients With Early Breast Cancer
Nadia Harbeck, MD, PhD
Read More
Original Research, COVID-19, Adverse Events, Infections
COVID-19 as a Primer for Drug-Induced Pneumonitis in Patients With Cancer
Avani Yenamandra, PharmD, BCOP; Alison Greidinger, MD; Jenia Jenab-Wolcott, MD, PhD
Read More
Review Article, Transplant, Adverse Events, Chemotherapy, Methotrexate
Hematopoietic Stem-Cell Transplantation and Drug Considerations in Transgender Patients
Erin Kate Barthelmess, PharmD, BCOP; Sarah Perreault, PharmD, BCPS, BCOP; Ashley Sabus, PharmD, BCOP; Jeffrey E. Topal, MD
Read More
FDA Updates
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Read More
FDA Updates
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Read More
ESMO Early Breast Cancer
Interview with the Innovators
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
Nadia Harbeck, MD, PhD
Read More
FDA Updates
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
Read More
FDA Updates
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
Read More
Page 30 of 199
Results 291 - 300 of 1986